Another line of evidence for this hypothesis is that treatment of cells from a premature aging disorder (HGPS) with metformin, a known activator of AMPK, decreases mRNA levels of SRSF1 and decreases the levels of pathologic alternative spliced lamin A (Egesipe et al. 2016). The gene discussed is SRSF1; the disease is Hutchinson-Gilford progeria syndrome.